Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2003-12-19
2008-08-12
Campell, Bruce (Department: 1648)
Chemistry: molecular biology and microbiology
Vector, per se
C435S015000, C435S235100, C424S184100
Reexamination Certificate
active
07410795
ABSTRACT:
The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators.
REFERENCES:
patent: 5124440 (1992-06-01), Gehrz et al.
patent: 5547834 (1996-08-01), Spaete et al.
patent: 5800981 (1998-09-01), Bruggeman et al.
patent: 5834307 (1998-11-01), Spaete et al.
patent: 6074648 (2000-06-01), Lee
patent: 6100064 (2000-08-01), Burke et al.
patent: 6133433 (2000-10-01), Pande et al.
patent: 6156317 (2000-12-01), Diamond et al.
patent: 6162620 (2000-12-01), Smith et al.
patent: 6242567 (2001-06-01), Pande et al.
patent: 6251399 (2001-06-01), Diamond et al.
patent: 2002/0081318 (2002-06-01), Zaia et al.
patent: 2002/0115067 (2002-08-01), Volker et al.
patent: 1 156 112 (2001-11-01), None
patent: WO 89/07143 (1989-08-01), None
patent: 0 609 580 (1994-08-01), None
patent: WO 97/11086 (1997-03-01), None
patent: WO 97/40165 (1997-10-01), None
patent: WO 99/02694 (1999-01-01), None
patent: WO 01/52888 (2001-07-01), None
Endresz et al. “Optimization of DNA immunization against human cytomegalovirus”. Vaccine. Jul. 16, 2001;19(28-29):3972-80.
Gonczol et al. “Development of a cytomegalovirus vaccine: lessons from recent clinical trials”. Expert Opin Biol Ther. May 2001;1(3):401-12.
Shiver et al. “Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity”. Nature. Jan. 17, 2002;415(6869):331-5.
Kotsopoulou et al. “A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene”. J Virol. May 2000;74(10):4839-52.
Baldridge “Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines”. Methods. Sep. 1999;19(1):103-7.
Nagata T ey al. “Codon Optimization Effect on Translational Efficiency of DNA Vaccine in Mammalian Cells: Analysis of Plasmid DNA Encoding a CTL Epitope Derived from Microorganisms” Biochemical and Biophysical research Communication; 261 (1999): 445-451.
European Examination Report for European Application No. 03 814 236.0-2405, European Patent Office, Munich.
Cranage, M.P., et al., “Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus,”EMBO J. 5:3057-3063, IRL Press Limited (1986).
Egan, M.A. and Israel, Z.R., “The use of cytokines and chemokines as genetic adjuvants for plasmid DNA vaccines,”Clin. Appl. Immunol. Rev. 2:255-287, Elsevier Science Inc. (Jul.-Sep. 2002).
EMBL-EBI Database, Accession No. P06473, Cranage, M.P., et al., Entry Date 1988, Updated Feb. 2006.
Shiver, J.W., et al., “Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity,”Nature 415:331-335, Macmillan Magazines Ltd. (Jan. 2002).
André, S., et al., “Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp120 Sequence with Optimized Codon Usage,”J. Virol. 72:1497-1503, American Society for Microbiology (1998).
Akrigg, A., et al., “The structure of the major immediate early gene of human cytomegalovirus strain AD169,”Virus Res. 2:107-121, Elsevier (1985).
Allen, L.B., et al., “Novel Method for Evaluating Antiviral Drugs against Human Cytomegalovirus in Mice,”Antimicrob. Agents Chemother. 36:206-208, American Society for Microbiology (1992).
Amadei, C., et al., “Human Anti-Cytomegalovirus (CMV) Immunoglobulins Secreted by EBV-Transformed B-Lymphocytes Cell Lines,”Dev. Biol. Stand. 57:283-286, S. Karger (1984).
Arrode, G., et al., “Cross-Presentation of Human Cytomegalovirus pp65 (UL83) to CD8+T Cells IsRegulated by Virus-Induced, Soluble-Mediator-Dependent Maturation of Dendritic Cells,”J. Virol. 76:142-150, American Society for Microbiology (Jan. 2002).
Berencsi, K., et al., “The N-terminal 303 amino acids of the human cytomegalovirus envelope glycoprotein B (UL55) and the exon 4 region of the major immediate early protein 1 (UL123) induce a cytotoxic T-cell response,”Vaccine 14:369-374, Elsevier Science, Ltd. (1996).
Bidanset, D.J., et al., “Replication of Human Cytomegalovirus in Severe Combined Immunodeficient Mice Implanted with Human Retinal Tissue,”J. Infect. Dis. 184:192-195, University of Chicago Press (Jul. 2001).
Chee, M.S., et al., “Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD169,” inCytomegaloviruses, McDougall, J.K., ed., Springer-Verlag, Berlin, pp. 126-169 (1990).
Davignon, J-L., et al., “Anti-Human Cytomegalovirus Activity of Cytokines Produced by CD4+T-Cell Clones Specifically Activated by IE1 Peptides In Vitro,”J. Virol. 70:2162-2169, American Society for Microbiology (1996).
Deml, L., et al., “Multiple Effects of Codon Usage Optimization on Expression and Immunogenicity of DNA Candidate Vaccines Encoding the Human Immunodeficiency Virus Type 1 Gag Protein,”J. Virol. 75:10991-11001, American Society for Microbiology (Nov. 2001).
Diamond, D.J., et al., “Development of a Candidate HLA A*0201 Restricted Peptide-Based Vaccine Against Human Cytomegalovirus Infection,”Blood 90:1751-1767, American Society of Hematology (1997).
Donnelly, J.J., et al., “DNA Vaccines,”Annu. Rev. Immunol. 15:617-648, Annual Reviews, Inc. (1997).
Elek, S.D., and Stern, H., “Development of a Vaccine Against Mental Retardation Caused by Cytomegalovirus Infection in Utero,”Lancet 1:1-5, The Lancet, Ltd. (1974).
Elkington, R., et al., “Ex Vivo Profiling of CD8+-T-Cell Responses to Human Cytomegalovirus Reveals Broad and Multispecific Reactivities in Healthy Virus Carriers,”J. Virol. 77:5226-5240, American Society for Microbiology (May 2003).
Endresz, V., et al., “Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization,”Vaccine 17:50-58, Elsevier Science, Ltd. (1999).
Endresz, V., et al., “Optimization of DNA immunization against human cytomegalovirus,”Vaccine 19:3972-3980, Elsevier Science, Ltd. (Jul. 2001).
Fowler, K.B., et al., “The Outcome of Congenital Cytomegalovirus Infection in Relation to Maternal Antibody Status,”N. Engl. J. Med. 326:663-667, Massachusetts Medical Society (1992).
Gallez-Hawkins, G., et al., “Kinase-Deficient CMVpp65 Triggers a CMVpp65 Specific T-Cell Immune Response in HLA-A*0201.KbTransgenic Mice after DNA Immunization,”Scand. J. Immunol. 55:592-598, Blackwell Science, Ltd. (Jun. 2002).
Gautier, N., et al., “Characterization of an epitope of the human cytomegalovirus protein IE1 recognized by a CD4+T cell clone,”Eur. J. Immunol. 26:1110-1117, VCH Verlagsgesellschaft mbH (1996).
Geissler, M., et al., “Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs,”
Geall Andrew J.
Hermanson Gary G.
Wloch Mary Kopke
Campell Bruce
Peng Bo
Sterne Kessler Goldstein & Fox P.L.L.C.
Vical Incorporated
LandOfFree
Codon-optimized polynucleotide-based vaccines against human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Codon-optimized polynucleotide-based vaccines against human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Codon-optimized polynucleotide-based vaccines against human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4013631